Herpesviruses, antiviral treatment, and the risk of dementia - systematic review and meta-analysis.

IF 7.6 1区 医学 Q1 CLINICAL NEUROLOGY
Nadia Jasmin Drinkall, Volkert Siersma, Richard Lathe, Gunhild Waldemar, Janet Janbek
{"title":"Herpesviruses, antiviral treatment, and the risk of dementia - systematic review and meta-analysis.","authors":"Nadia Jasmin Drinkall, Volkert Siersma, Richard Lathe, Gunhild Waldemar, Janet Janbek","doi":"10.1186/s13195-025-01838-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this systematic review and meta-analysis was to synthesize the evidence on the association between herpesviruses, antiviral treatment, and the risk of dementia. We also aimed to explore the impact of time between herpesviruses and dementia on the reported associations.</p><p><strong>Methods: </strong>PubMed and Web of Science were searched along with reference lists of the included studies. We included studies that looked at clinical episodes or serology (IgG/IgM) of herpes simplex virus type 1/2 (HSV1/2) and/or varicella zoster virus (VZV), antiviral treatment and incident dementia (all-cause dementia, Alzheimer's disease, and vascular dementia). Study results were pooled with random effect meta-analyses.</p><p><strong>Results: </strong>We included 32 studies. The pooled hazard ratio for all-cause dementia was 1.36 [95% CI: 1.01, 1.83] following a clinical episode of HSV1/2, and 1.12 [95% CI: 1.00, 1.25] following a clinical episode of VZV. The pooled estimate for all-cause dementia following antiviral treatment and VZV was 0.88 [95% CI: 0.81, 0.96].</p><p><strong>Conclusions: </strong>The present review of the scientific literature generally shows little evidence of an association between herpesviruses and risk of dementia. However, the review shows evidence of an association between antiviral treatment and a decreased risk of dementia. Because of considerable heterogeneity, future investigations could advantageously target certain subgroups.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"17 1","pages":"201"},"PeriodicalIF":7.6000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403512/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-025-01838-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The aim of this systematic review and meta-analysis was to synthesize the evidence on the association between herpesviruses, antiviral treatment, and the risk of dementia. We also aimed to explore the impact of time between herpesviruses and dementia on the reported associations.

Methods: PubMed and Web of Science were searched along with reference lists of the included studies. We included studies that looked at clinical episodes or serology (IgG/IgM) of herpes simplex virus type 1/2 (HSV1/2) and/or varicella zoster virus (VZV), antiviral treatment and incident dementia (all-cause dementia, Alzheimer's disease, and vascular dementia). Study results were pooled with random effect meta-analyses.

Results: We included 32 studies. The pooled hazard ratio for all-cause dementia was 1.36 [95% CI: 1.01, 1.83] following a clinical episode of HSV1/2, and 1.12 [95% CI: 1.00, 1.25] following a clinical episode of VZV. The pooled estimate for all-cause dementia following antiviral treatment and VZV was 0.88 [95% CI: 0.81, 0.96].

Conclusions: The present review of the scientific literature generally shows little evidence of an association between herpesviruses and risk of dementia. However, the review shows evidence of an association between antiviral treatment and a decreased risk of dementia. Because of considerable heterogeneity, future investigations could advantageously target certain subgroups.

Abstract Image

Abstract Image

Abstract Image

疱疹病毒、抗病毒治疗和痴呆风险——系统回顾和荟萃分析。
本系统综述和荟萃分析的目的是综合疱疹病毒、抗病毒治疗和痴呆风险之间关联的证据。我们还旨在探讨疱疹病毒和痴呆之间的时间对报道的关联的影响。方法:检索PubMed和Web of Science以及纳入研究的参考文献。我们纳入了单纯疱疹病毒1/2型(HSV1/2)和/或水痘带状疱疹病毒(VZV)的临床发作或血清学(IgG/IgM)、抗病毒治疗和痴呆事件(全因痴呆、阿尔茨海默病和血管性痴呆)的研究。研究结果采用随机效应荟萃分析。结果:我们纳入了32项研究。HSV1/2临床发作后全因痴呆的合并风险比为1.36 [95% CI: 1.01, 1.83], VZV临床发作后全因痴呆的合并风险比为1.12 [95% CI: 1.00, 1.25]。抗病毒治疗和VZV后全因痴呆的合并估计为0.88 [95% CI: 0.81, 0.96]。结论:目前对科学文献的回顾显示,疱疹病毒与痴呆风险之间的关联证据很少。然而,该综述显示抗病毒治疗与痴呆风险降低之间存在关联的证据。由于相当大的异质性,未来的研究可以有利地针对某些亚群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy 医学-神经病学
CiteScore
13.10
自引率
3.30%
发文量
172
审稿时长
>12 weeks
期刊介绍: Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信